# Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

> **NCT04936295** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 61 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fulvestrant plus Anlotinib

## Key facts

- **NCT ID:** NCT04936295
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-16
- **Primary completion:** 2023-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2021-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04936295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04936295, "Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04936295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*